Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Prostatic Neoplasms, Small Cell Lung Carcinoma

NCT06844383 2025-10-29

TALENT

Phase 2 Recruiting

126 enrolled

Genitourinary

Adenocarcinoma, Prostatic Neoplasms

NCT06922318 2025-09-17

The COSMYC Trial (COmbined Suppression of MYC)

Phase 2 Recruiting

50 enrolled

Genitourinary

Prostatic Neoplasms

NCT05413421 2025-08-11

Study of ORIC-944 in Patients With Metastatic Prostate Cancer

Phase 1 Recruiting

250 enrolled

Genitourinary

Prostatic Neoplasms

NCT06520345 2025-07-10

The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)

Phase 3 Recruiting

430 enrolled

Genitourinary

Prostatic Neoplasms

NCT06652607 2025-03-12

PSA-DEEP02

Recruiting

152 enrolled

Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT06582628 2024-12-02

TEAM PC

Phase 2 Recruiting

78 enrolled

Genitourinary

Prostatic Diseases, Prostatic Neoplasms

NCT05393791 2024-11-26

ANZadapt

Phase 2 Recruiting

168 enrolled

Genitourinary

Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT05404139 2024-11-25

DIRECT

Phase 2 Recruiting

132 enrolled

Genitourinary

Prostatic Neoplasms

NCT06473259 2024-06-25

ECHOS

Recruiting

3,000 enrolled

Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT03753243 2022-04-20

Neoadjuvant Pembrolizumab Plus Androgen Axis Blockade Prior to Prostatectomy for High Risk Localized Prostate Cancer

Phase 2 Recruiting

32 enrolled

Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Prostatic Neoplasms

Clinical Trials

MK-5684-004

TRIPLE-SWITCH

A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Double-DARE

VA STARPORT

PREDICT

EvoPAR-PR01

Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

MEVPRO-3

Enzalutamide and PDS01ADC in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Therapy

A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer

Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer

Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer

MEVPRO-1

A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer

AMX-500

AcTFirst

Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer

A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer

rechARge

Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer

DIVINE

Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer

PRO-MIND

A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

TALENT

The COSMYC Trial (COmbined Suppression of MYC)

Study of ORIC-944 in Patients With Metastatic Prostate Cancer

The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)

PSA-DEEP02

TEAM PC

ANZadapt

DIRECT

ECHOS

Neoadjuvant Pembrolizumab Plus Androgen Axis Blockade Prior to Prostatectomy for High Risk Localized Prostate Cancer